Prostate Cancer Diagnostics and Minimally Invasive Treatments Market
Prostate Cancer Diagnostics and Minimally Invasive Treatments Market
$4,750.00
This report includes a discussion of leading products, new technologies, market forecasts, drivers and limiters, competitors, trends & opportunities in the nearly $1bn Prostate Cancer Diagnostics and Minimally Invasive Treatments market.
Publisher: Meddevicetracker
- Highlights
- Description
- Contents
Key Questions Answered
- What is the value of the prostate cancer diagnostics and minimally invasive treatments market? Expected growth?
- Estimated sales and growth by segment and region?
- Key market drivers and limiters?
- New products and innovations?
- Leading competitors?
- Estimate market share?
- Startups or emerging competitors?
- Trends & opportunities?
ICD Highlights
- The global prostate cancer diagnostic products market was valued at nearly $270m in 2018. The market is expected to increase at a healthy rate, at more than 11% CAGR.
- The global minimally invasive prostate cancer treatments market was valued at more than $630m in 2018. The market is expected to increase at a CAGR slightly under 10%.
- The diagnostics market will be driven by growth in sales of advanced, precise/targeted MRI-US fusion biopsy systems and noninvasive molecular diagnostics/liquid biopsy tests capable of “ruling out” unnecessary biopsies and potentially supplementing less-than reliable PSA tests.
- The minimally invasive treatments market will be driven by sales of robotic-assisted laparoscopic prostatectomy (RALP) instruments/accessories, ablation systems (particularly high-intensity focused ultrasound or HIFU and cryoablation), and the small but growing market of hydrogel spacers for protecting prostate tissue during radiotherapy.
Overview
Prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. Approximately 1 in 7 men will be diagnosed with prostate cancer in their lifetime.
This report provides an indepth analysis of the Global Prostate Cancer Diagnostics and Minimally Invasive Treatments Market, estimated at nearly $1 billion in combined sales in 2018. The total market is forecast to experience healthy growth of more than 10% CAGR.
The market will be driven by new and promising noninvasive diagnostic tests, such as emerging molecular diagnostics/liquid biopsy technologies used to help to “rule out” biopsy, or prevent unnecessary biopsies, in low-risk prostate cancer patients. These improved assays will continue to spur market momentum and supplement, or perhaps someday replace less-than reliable PSA tests.
Other new diagnostics technologies, such as targeted prostate biopsy using MRI-ultrasound (MRI-US) fusion, is allowing accurate diagnosis of serious tumors not typically found with conventional biopsy, while providing a method for repeat biopsy of specific tumor-bearing sites for men in active surveillance. Fusion devices are allowing the urologist to combine MRI and other images to more accurately guide prostate biopsy in an outpatient clinic setting.
Several minimally invasive prostate cancer treatment products will also spur market growth, including instruments and accessories used in robotic-assisted laparoscopic prostatectomy (RALP); brachytherapy products; ablation systems (particularly, high-intensity focused ultrasound/HIFU and cryoablation); and novel hydrogel spacers for protecting healthy tissue during prostate radiotherapy.
The report provides the following useful information:
- an epidemiological overview of prostate cancer
- analysis of selected leading diagnostic and minimally invasive treatment products for prostate cancer
- competitive analysis, including estimated market share and emerging competition
- insight into factors driving and limiting market growth
- estimated five-year market forecasts.
Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which includes all other countries.
Table of Contents
Executive Summary ……………………………………………………………………………………………… ES-1
i. Prostate cancer overview………………………………………………………………………………………ES-1
ii. Prostate cancer diagnostics and minimally invasive treatments market …………………….ES-1
a. Market drivers and limiters……………………………………………………………………….ES-6
b. Technology trends …………………………………………………………………………………..ES-6
c. Market leaders………………………………………………………………………………………..ES-7
d. Competitive strategies……………………………………………………………………………..ES-7
e. Emerging competition………………………………………………………………………………ES-7
iii. Methodology……………………………………………………………………………………………………..ES-7
iv. Bibliography …………………………………………………………………………………………………….ES-10
Exhibit ES-1: Prostate cancer diagnostic products, global market forecast 2018-23…………… ES-3
Exhibit ES-2: Minimally invasive prostate cancer treatments, global market forecast 2018-23 ………………………………………………………………………………… ES-5
1. Prostate Cancer Overview…………………………………………………………………………………….1-1
1.1 Staging …………………………………………………………………………………………………………….. 1-1
1.2 Incidence: US, 5EU and Japan……………………………………………………………………………… 1-1
1.3 Risk factors……………………………………………………………………………………………………….. 1-3
1.3.1 Genetics…………………………………………………………………………………………….. 1-4
1.4 Detection and diagnosis…………………………………………………………………………………….. 1-4
1.4.1 PSA testing …………………………………………………………………………………………. 1-5
1.4.2 Screening……………………………………………………………………………………………. 1-6
1.4.3 Biopsy………………………………………………………………………………………………… 1-7
1.4.4 Molecular diagnostics and liquid biopsy……………………………………………….. 1-13
1.5 Prostate Cancer Treatment pathways………………………………………………………………… 1-14
1.5.1 Surgery …………………………………………………………………………………………….. 1-15
1.5.2 Focal therapies………………………………………………………………………………….. 1-17
1.5.3 Chemotherapy ………………………………………………………………………………….. 1-25
1.5.4 Radiation therapy ……………………………………………………………………………… 1-25
1.5.5 Hormonal therapy……………………………………………………………………………… 1-27
1.5.6 Biological treatments…………………………………………………………………………. 1-28
1.6 Bibliography ……………………………………………………………………………………………………. 1-29
Exhibit 1-1: Estimated new cases of prostate cancer by stage, US, 2018 and 2023 ………………1-2
Exhibit 1-2: Estimated new cases of prostate cancer by stage, 5EU, 2018 and 2023……………..1-2
Exhibit 1-3: Estimated new cases of prostate cancer by stage, Japan, 2018 and 2023…………..1-3
Exhibit 1-4: Advantages and disadvantages of multiparametric MRI for prostate imaging…..1-10
Exhibit 1-5: Advantages and disadvantages of liquid biopsy………………………………………….1-14
Exhibit 1-6: Treatment options for prostate cancer by cancer type/stage ………………………..1-15
Exhibit 1-7: Surgical options for prostate cancer…………………………………………………………1-16
Exhibit 1-8: HIFU for prostate cancer using the transrectal approach………………………………1-20
Exhibit 1-9: Advantages/disadvantages of HIFU for prostate cancer treatment ………………..1-22
Exhibit 1-10: Advantages/disadvantages of IRE for prostate cancer treatment …………………1-23
2. Prostate Cancer Diagnostics………………………………………………………………………………….2-1
2.1 PSA tests…………………………………………………………………………………………………………… 2-1
2.2 Molecular diagnostic and liquid biopsy products…………………………………………………… 2-2
2.3 Biopsy guidance systems ……………………………………………………………………………………. 2-5
2.3.1 Emerging biopsy products/technologies………………………………………………… 2-9
2.4 Prostate cancer diagnostic products market…………………………………………………………. 2-9
2.4.1 Global market insights……………………………………………………………………….. 2-10
2.4.2 Market value…………………………………………………………………………………….. 2-10
2.4.3 Segment insights……………………………………………………………………………….. 2-12
2.4.4 Regional insights……………………………………………………………………………….. 2-15
2.4.5 Market trends…………………………………………………………………………………… 2-26
2.4.6 Market drivers and limiters ………………………………………………………………… 2-27
2.4.7 Market share…………………………………………………………………………………….. 2-28
2.5 Bibliography ……………………………………………………………………………………………………. 2-30
Exhibit 2-1: Selected molecular diagnostic/liquid biopsy products for prostate cancer……….2-4
Exhibit 2-2: Selected commercially available MRI-US fusion biopsy systems for prostate cancer diagnosis……………………………………………………………………….2-7
Exhibit 2-3: Prostate cancer diagnostic products, combined market forecast, by product segment, 2018-23…………………………………………………………………….2-11
Exhibit 2-4: Prostate cancer diagnostic products, US market forecast, 2018-2023…………….2-16
Exhibit 2-5: Prostate cancer diagnostic products, 5EU market forecast, 2018-2023…………..2-19
Exhibit 2-6: Prostate cancer diagnostic products, Japan market forecast, 2018-2023………..2-22
Exhibit 2-7: Prostate cancer diagnostic products, RoW market forecast, 2018-2023 …………2-24
Exhibit 2-8: 2018, Prostate cancer diagnostic products market, share by supplier ……………2-29
3. Minimally Invasive Prostate Cancer Treatments ……………………………………………………….3-1
3.1 Prostate cancer surgery ……………………………………………………………………………………… 3-1
3.1.1 Robotic-assisted laparoscopic prostatectomy (RALP) products…………………. 3-1
3.2 Prostate radiation therapy………………………………………………………………………………….. 3-5
3.2.1 EBRT ………………………………………………………………………………………………… 3-6
3.2.2 Brachytherapy…………………………………………………………………………………….. 3-9
3.2.3 Hydrogel spacers for radiotherapy ………………………………………………………. 3-15
3.3 Ablation of prostate cancer ………………………………………………………………………………. 3-16
3.3.1 Cryoablation……………………………………………………………………………………… 3-16
3.3.2 High-intensity focused ultrasound……………………………………………………….. 3-18
3.3.3 Irreversible electroporation (IRE) ………………………………………………………… 3-25
3.4 Minimally invasive prostate cancer treatments market………………………………………… 3-25
3.4.1 Market value…………………………………………………………………………………….. 3-26
3.4.2 Segment insights……………………………………………………………………………….. 3-28
3.4.3 Regional insights……………………………………………………………………………….. 3-30
3.4.4 Market trends…………………………………………………………………………………… 3-44
3.4.5 Market drivers and limiters ………………………………………………………………… 3-45
3.4.6 Market leaders………………………………………………………………………………….. 3-46
3.5 Bibliography ……………………………………………………………………………………………………. 3-49
3.6 Appendix ………………………………………………………………………………………………………… 3-56
3.6.1 Prostate cancer ablation survey ………………………………………………………….. 3-56
Exhibit 3-1: Minimally invasive prostate cancer treatments, combined market forecast, by product segment 2018-2023 ………………………………………3-27
Exhibit 3-2: Minimally invasive prostate cancer treatments, US market forecast, 2018-2023 …………………………………………………………………………….3-31
Exhibit 3-3: Minimally invasive prostate cancer treatments, 5EU market forecast, 2018-2023 …………………………………………………………………………….3-34
Exhibit 3-4: Minimally invasive prostate cancer treatments, Japanese market forecast, 2018-2023 …………………………………………………………………………….3-38
Exhibit 3-5: Minimally invasive prostate cancer treatments, RoW market forecast, 2018-2023 …………………………………………………………………………….3-42
Exhibit 3-6: Minimally invasive prostate cancer treatments, forecast by region, 2018-2023 ……………………………………………………………….3-43
Exhibit 3-7: 2018, Minimally invasive prostate cancer treatments, share by supplier ………………………………………………………………………………..3-48
Appendix A: company listing
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the